Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction ...
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.